{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:53:32Z","timestamp":1790963612802,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T00:00:00Z","timestamp":1444176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T00:00:00Z","timestamp":1444176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1038\/leu.2015.273","type":"journal-article","created":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T06:41:47Z","timestamp":1444200107000},"page":"346-350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"30","author":[{"given":"K A","family":"Rogers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A S","family":"Ruppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Bingman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L A","family":"Andritsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F T","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K A","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S M","family":"Jaglowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Lozanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K J","family":"Maddocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J C","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Woyach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,7]]},"reference":[{"key":"BFleu2015273_CR1","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1053\/j.seminoncol.2006.01.011","volume":"33","author":"TJ Hamblin","year":"2006","unstructured":"Hamblin TJ . Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006; 33: 230\u2013239.","journal-title":"Semin Oncol"},{"key":"BFleu2015273_CR2","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1182\/blood-2010-05-286500","volume":"116","author":"C Moreno","year":"2010","unstructured":"Moreno C, Hodgson K, Ferrer G, Elena M, Filella X, Pereira A et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood 2010; 116: 4771\u20134776.","journal-title":"Blood"},{"key":"BFleu2015273_CR3","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1182\/blood.V95.9.2786.009k30_2786_2792","volume":"95","author":"FR Mauro","year":"2000","unstructured":"Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000; 95: 2786\u20132792.","journal-title":"Blood"},{"key":"BFleu2015273_CR4","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3109\/10428194.2013.834054","volume":"55","author":"C Visco","year":"2014","unstructured":"Visco C, Cortelezzi A, Moretta F, Falisi E, Maura F, Finotto S et al. Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C? Leuk Lymphoma 2014; 55: 1261\u20131265.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2015273_CR5","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/ajh.20665","volume":"81","author":"G D\u2019Arena","year":"2006","unstructured":"D\u2019Arena G, Laurenti L, Capalbo S, D\u2019Arco AM, De Filippi R, Marcacci G et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 2006; 81: 598\u2013602.","journal-title":"Am J Hematol"},{"key":"BFleu2015273_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1365-2141.1995.tb05300.x","volume":"91","author":"H Myint","year":"1995","unstructured":"Myint H, Copplestone JA, Orchard J, Craig V, Curtis D, Prentice AG et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91: 341\u2013344.","journal-title":"Br J Haematol"},{"key":"BFleu2015273_CR7","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1200\/JCO.1998.16.5.1885","volume":"16","author":"RB Weiss","year":"1998","unstructured":"Weiss RB, Freiman J, Kweder SL, Diehl LF, Byrd JC . Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998; 16: 1885\u20131889.","journal-title":"J Clin Oncol"},{"key":"BFleu2015273_CR8","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164\u20131174.","journal-title":"Lancet"},{"key":"BFleu2015273_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","volume":"370","author":"D Catovsky","year":"2007","unstructured":"Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230\u2013239.","journal-title":"Lancet"},{"key":"BFleu2015273_CR10","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1182\/blood-2007-07-101303","volume":"111","author":"C Dearden","year":"2008","unstructured":"Dearden C, Wade R, Else M, Richards S, Milligan D, Hamblin T et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 2008; 111: 1820\u20131826.","journal-title":"Blood"},{"key":"BFleu2015273_CR11","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","volume":"120","author":"JA Woyach","year":"2012","unstructured":"Woyach JA, Johnson AJ, Byrd JC . The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012; 120: 1175\u20131184.","journal-title":"Blood"},{"key":"BFleu2015273_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32\u201342.","journal-title":"N Engl J Med"},{"key":"BFleu2015273_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, Barrientos JC, Kay NE, Reddy NM et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213\u2013223.","journal-title":"N Engl J Med"},{"key":"BFleu2015273_CR14","unstructured":"Ibrutinib Full Prescribing Information. [Web Page] 1\/2015 [cited 2\/2015]; Available from http:\/\/www.imbruvica.com\/docs\/librariesprovider3\/default-document-library\/prescribing_information.pdf?sfvrsn=2 (accessed 1 February 2015)."},{"key":"BFleu2015273_CR15","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/MD.0b013e3181f2caef","volume":"89","author":"O Wolach","year":"2010","unstructured":"Wolach O, Bairey O, Lahav M . Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine 2010; 89: 308\u2013318.","journal-title":"Medicine"},{"key":"BFleu2015273_CR16","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1056\/NEJM200306263482620","volume":"348","author":"E Voog","year":"2003","unstructured":"Voog E, Morschhauser F, Solal-Celigny P . Neutropenia in patients treated with rituximab. N Engl J Med 2003; 348: 2691\u20132694, discussion 2691\u20132694.","journal-title":"N Engl J Med"},{"key":"BFleu2015273_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1053\/j.seminhematol.2010.01.009","volume":"47","author":"K Dunleavy","year":"2010","unstructured":"Dunleavy K, Tay K, Wilson WH . Rituximab-associated neutropenia. Semin Hematol 2010; 47: 180\u2013186.","journal-title":"Semin Hematol"},{"key":"BFleu2015273_CR18","unstructured":"Elwood JM . Causal Relationships in Medicine: A Practical System for Critical Appraisal. Oxford University Press: New York, NY, USA, 1988, xi+332 pp."},{"key":"BFleu2015273_CR19","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H Dohner","year":"2000","unstructured":"Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910\u20131916.","journal-title":"N Engl J Med"},{"key":"BFleu2015273_CR20","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","volume":"94","author":"TJ Hamblin","year":"1999","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848\u20131854.","journal-title":"Blood"},{"key":"BFleu2015273_CR21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.V124.21.22.22","volume":"124","author":"PA Thompson","year":"2014","unstructured":"Thompson PA, Wierda WG, Ferrajoli A, Smith SC, O\u2019Brien S, Burger JA et al. Complex karyotype, rather than Del(17p), is associated with inferior outcomes in relapsed or refractory CLL patients treated with ibrutinib-based regimens. Blood 2014; 124: 22\u201322.","journal-title":"Blood"},{"key":"BFleu2015273_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/ajh.23342","volume":"88","author":"F Maura","year":"2013","unstructured":"Maura F, Visco C, Falisi E, Reda G, Fabris S, Agnelli L et al. B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia. Am J Hematol 2013; 88: 32\u201336.","journal-title":"Am J Hematol"},{"key":"BFleu2015273_CR23","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1182\/blood-2014-05-578823","volume":"124","author":"KA Rogers","year":"2014","unstructured":"Rogers KA, Woyach JA, Andritsos LA, Awan F, Blum KA, Flynn JM et al. Incidence of autoimmune cytopenias (AIC) in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL\/SLL) Patients (pts) treated with ibrutinib. Blood 2014; 124: 1997\u20131997.","journal-title":"Blood"},{"key":"BFleu2015273_CR24","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1182\/blood.V124.21.5654.5654","volume":"124","author":"M Montillo","year":"2014","unstructured":"Montillo M, O\u2019Brien S, Tedeschi A, Hillmen P, Dearden C, Gill D et al. Autoimmune hemolytic anemia and immune mediated thrombocytopenia in the phase III RESONATETM study of ibrutinib vs ofatumumab in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma, including a case report. Blood 2014; 124: 5654\u20135654.","journal-title":"Blood"},{"key":"BFleu2015273_CR25","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1080\/10428190903026492","volume":"50","author":"CS Zent","year":"2009","unstructured":"Zent CS, Ding W, Reinalda MS, Schwager SM, Hoyer JD, Bowen DA et al. Autoimmune cytopenia in chronic lymphocytic leukemia\/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leuk Lymphoma 2009; 50: 1261\u20131268.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2015273_CR26","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1182\/blood-2003-10-3563","volume":"105","author":"AM Hall","year":"2005","unstructured":"Hall AM, Vickers MA, McLeod E, Barker RN . Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 2005; 105: 2007\u20132015.","journal-title":"Blood"},{"key":"BFleu2015273_CR27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3109\/10428199609052430","volume":"20","author":"M Centola","year":"1996","unstructured":"Centola M, Lin K, Sutton C, Berenson JR, Kunkel LA, Rosen L et al. Production of anti-erythrocyte antibodies by leukemic and nonleukemic B cells in chronic lymphocytic leukemia patients. Leuk Lymphoma 1996; 20: 465\u2013469.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2015273_CR28","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3109\/10428194.2012.728287","volume":"54","author":"DP Lad","year":"2013","unstructured":"Lad DP, Varma S, Varma N, Sachdeva MU, Bose P, Malhotra P . Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias. Leuk Lymphoma 2013; 54: 1012\u20131019.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2015273_CR29","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013; 122: 2539\u20132549.","journal-title":"Blood"},{"key":"BFleu2015273_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/08916930290005891","volume":"35","author":"E Fagiolo","year":"2002","unstructured":"Fagiolo E, Toriani-Terenzi C . Th1 and Th2 cytokine modulation by IL-10\/IL-12 imbalance in autoimmune haemolytic anaemia (AIHA). Autoimmunity 2002; 35: 39\u201344.","journal-title":"Autoimmunity"},{"key":"BFleu2015273_CR31","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1073\/pnas.1424907112","volume":"112","author":"M Feng","year":"2015","unstructured":"Feng M, Chen JY, Weissman-Tsukamoto R, Volkmer JP, Ho PY, McKenna KM et al. Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk. Proc Natl Acad Sci USA 2015; 112: 2145\u20132150.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2015273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015273","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2015.273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:06:38Z","timestamp":1648742798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,7]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["BFleu2015273"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.273","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,7]]},"assertion":[{"value":"23 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JAJ has served as a consultant for Pharmacyclics and Janssen. KJM has received research support from Pharmacyclics. KAB has received research funding from Pharmacyclics and Janssen. SMJ has received research funding and has served as a consultant for Pharmacyclics. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}